Sorafenib in Treating Patients With Advanced or Metastatic Cancer of the Urinary Tract
Status:
Completed
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well sorafenib works in treating patients with advanced
or metastatic cancer of the urinary tract. Sorafenib may stop the growth of tumor cells by
blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.